Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).
EURneffy is the first needle-free adrenaline treatment option in the EU, offering a more convenient and accessible alternative for adults and children with severe allergies.
It represents the first novel adrenaline delivery method in more than three decades, according to Richard Lowenthal, co-founder, president and CEO of ARS Pharma.
ARS Pharma anticipates that EURneffy will be available to patients in certain European Union member states in the fourth quarter of 2024.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China